Cite

HARVARD Citation

    Hellmann, M. et al. (n.d.). 3097 Safety and efficacy of first-line nivolumab (NIVO) and ipilimumab (IPI) in non-small cell lung cancer (NSCLC). European journal of cancer. pp. S632-S633. [Online]. 
  
Back to record